Scandinavian ChemoTech AB Series B (CMOTEC-B) - Net Assets
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has net assets worth Skr1.52 Million SEK (≈ $163.58K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr11.01 Million ≈ $1.18 Million USD) and total liabilities (Skr9.49 Million ≈ $1.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CMOTEC-B strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr1.52 Million |
| % of Total Assets | 13.81% |
| Annual Growth Rate | 46.92% |
| 5-Year Change | -86.68% |
| 10-Year Change | -78.15% |
| Growth Volatility | 651.1 |
Scandinavian ChemoTech AB Series B - Net Assets Trend (2014–2025)
This chart illustrates how Scandinavian ChemoTech AB Series B's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Scandinavian ChemoTech AB Series B.
Annual Net Assets for Scandinavian ChemoTech AB Series B (2014–2025)
The table below shows the annual net assets of Scandinavian ChemoTech AB Series B from 2014 to 2025. Also explore CMOTEC-B net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr3.19 Million ≈ $342.86K |
-46.72% |
| 2024-12-31 | Skr5.98 Million ≈ $643.54K |
-45.79% |
| 2023-12-31 | Skr11.03 Million ≈ $1.19 Million |
-21.16% |
| 2022-12-31 | Skr13.99 Million ≈ $1.51 Million |
-41.50% |
| 2021-12-31 | Skr23.92 Million ≈ $2.57 Million |
+158.95% |
| 2020-12-31 | Skr9.24 Million ≈ $993.94K |
-5.07% |
| 2019-12-31 | Skr9.73 Million ≈ $1.05 Million |
-52.53% |
| 2018-12-31 | Skr20.50 Million ≈ $2.21 Million |
+99.23% |
| 2017-12-31 | Skr10.29 Million ≈ $1.11 Million |
-29.46% |
| 2016-12-31 | Skr14.58 Million ≈ $1.57 Million |
+1578.88% |
| 2015-12-31 | Skr868.64K ≈ $93.48K |
+1777.36% |
| 2014-12-31 | Skr46.27K ≈ $4.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Scandinavian ChemoTech AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 805040600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr12.73 Million | 399.47% |
| Total Equity | Skr3.19 Million | 100.00% |
Scandinavian ChemoTech AB Series B Competitors by Market Cap
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASKOLL EVA S.P.A.
F:736
|
$8.71 Million |
|
Swift Networks Group Ltd
AU:SW1
|
$8.71 Million |
|
Dnonce Tech Bhd
KLSE:7114
|
$8.72 Million |
|
ICDS Limited
NSE:ICDSLTD
|
$8.72 Million |
|
Harper Hygienics S.A.
WAR:HRP
|
$8.71 Million |
|
Canterbury Resources Ltd
AU:CBY
|
$8.71 Million |
|
Churchill Resources Inc
V:CRI
|
$8.71 Million |
|
Celsius Resources Limited
F:FX8
|
$8.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandinavian ChemoTech AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,980,000 to 3,186,000, a change of -2,794,000 (-46.7%).
- Net loss of 8,055,999 reduced equity.
- New share issuances of 5,088,000 increased equity.
- Other comprehensive income increased equity by 108,869,000.
- Other factors decreased equity by 108,695,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.06 Million | -252.86% |
| Share Issuances | Skr5.09 Million | +159.7% |
| Other Comprehensive Income | Skr108.87 Million | +3417.11% |
| Other Changes | Skr-108.70 Million | -3411.64% |
| Total Change | Skr- | -46.72% |
Book Value vs Market Value Analysis
This analysis compares Scandinavian ChemoTech AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.64x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 130.27x to 25.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.03 | Skr3.40 | x |
| 2014-12-31 | Skr0.03 | Skr3.40 | x |
| 2015-12-31 | Skr0.76 | Skr3.40 | x |
| 2016-12-31 | Skr9.98 | Skr3.40 | x |
| 2017-12-31 | Skr7.03 | Skr3.40 | x |
| 2018-12-31 | Skr6.28 | Skr3.40 | x |
| 2019-12-31 | Skr2.37 | Skr3.40 | x |
| 2020-12-31 | Skr1.88 | Skr3.40 | x |
| 2021-12-31 | Skr2.76 | Skr3.40 | x |
| 2022-12-31 | Skr1.40 | Skr3.40 | x |
| 2023-12-31 | Skr0.79 | Skr3.40 | x |
| 2024-12-31 | Skr0.26 | Skr3.40 | x |
| 2025-12-31 | Skr0.13 | Skr3.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandinavian ChemoTech AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -252.86%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.58%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 4.14x
- Recent ROE (-252.86%) is below the historical average (-118.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -16.80% | 0.00% | 0.00x | 1.00x | Skr-11.90K |
| 2014 | -60.81% | 0.00% | 0.00x | 1.42x | Skr-32.76K |
| 2015 | -135.94% | -8498.88% | 0.00x | 7.66x | Skr-1.27 Million |
| 2016 | -55.81% | -390.48% | 0.12x | 1.15x | Skr-9.60 Million |
| 2017 | -80.99% | -30582.56% | 0.00x | 1.25x | Skr-9.36 Million |
| 2018 | -23.41% | -856.61% | 0.02x | 1.11x | Skr-6.85 Million |
| 2019 | -129.36% | -2263.49% | 0.03x | 1.80x | Skr-13.56 Million |
| 2020 | -126.29% | -8903.82% | 0.01x | 1.73x | Skr-12.59 Million |
| 2021 | -74.19% | -36210.20% | 0.00x | 1.08x | Skr-20.13 Million |
| 2022 | -162.56% | -4808.88% | 0.02x | 1.55x | Skr-24.15 Million |
| 2023 | -191.20% | -747.38% | 0.19x | 1.35x | Skr-22.19 Million |
| 2024 | -229.38% | -208.91% | 0.49x | 2.24x | Skr-14.31 Million |
| 2025 | -252.86% | -65.58% | 0.93x | 4.14x | Skr-8.37 Million |
Industry Comparison
This section compares Scandinavian ChemoTech AB Series B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $247,723,377
- Average return on equity (ROE) among peers: -93.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandinavian ChemoTech AB Series B (CMOTEC-B) | Skr1.52 Million | -16.80% | 6.24x | $8.71 Million |
| 2cureX AB (2CUREX) | $12.08 Million | -269.23% | 0.35x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $307.83 Million | -40.90% | 0.08x | $8.46 Million |
| AcouSort AB (ACOU) | $9.96 Million | -8.34% | 0.21x | $6.86 Million |
| Active Biotech AB (ACTI) | $77.68 Million | -140.06% | 2.91x | $11.62 Million |
| Alzinova AB (ALZ) | $59.11 Million | -10.49% | 0.07x | $8.77 Million |
| AlzeCure Pharma (ALZCUR) | $26.18 Million | -134.56% | 0.32x | $93.99 Million |
| Annexin Pharmaceuticals AB (ANNX) | $11.49 Million | -247.14% | 0.40x | $7.83 Million |
| Alligator Bioscience AB (ATORX) | $258.50 Million | -81.44% | 0.20x | $2.11 Million |
| BioInvent International AB (BINV) | $1.61 Billion | -2.12% | 0.07x | $157.21 Million |
| BioArctic AB (publ) (BIOA-B) | $108.28 Million | 3.43% | 0.21x | $2.62 Billion |
About Scandinavian ChemoTech AB Series B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTe… Read more